Reduction of early ventricular arrhythmia by acebutolol in patients with acute myocardial infarction

G. G. Ahumada, R. P. Karlsberg, Allan S Jaffe, H. D. Ambos, B. E. Sobel, R. Roberts

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

To assess the effects of intravenously administered acebutolol (1-20 mg every 4 hours for 24 hours) on cardiac rhythm and performance, we studied 72 patients with evolving myocardial infarction. Twenty-five patients were treated with acebutolol beginning 6 hours after the first increase in the level of plasma creatine kinase. Enzymatically estimated infarct size was compared with that of 25 controls matched for predicted infarct size. Observed infarct sizes were not significantly different in the 2 groups (37±5 and 30±5 CK-gram equivalents, respectively). Mean heart rate, diastolic blood pressure, and cardiac output declined from control values during treatment with acebutolol, but remained within the normal range. Mean pulmonary artery pressure and pulmonary artery occlusive pressure were unchanged. In a group of 22 treated patients matched with 22 control subjects for frequency of ventricular extrasystoles, acebutolol effected a prompt reduction in frequencies of ventricular extrasystoles and repetitive arrhythmias, whereas values were not significantly changed in controls during the corresponding intervals. Accordingly, acebutolol may be a useful antiarrhythmic agent in selected patients with acute myocardial infarction without adversely altering haemodynamic stability or enzymatically estimated infarct size.

Original languageEnglish (US)
Pages (from-to)654-659
Number of pages6
JournalBritish Heart Journal
Volume41
Issue number6
StatePublished - 1979
Externally publishedYes

Fingerprint

Acebutolol
Cardiac Arrhythmias
Myocardial Infarction
Ventricular Premature Complexes
Pulmonary Artery
Blood Pressure
Pressure
Creatine Kinase
Cardiac Output
Reference Values
Heart Rate
Hemodynamics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Ahumada, G. G., Karlsberg, R. P., Jaffe, A. S., Ambos, H. D., Sobel, B. E., & Roberts, R. (1979). Reduction of early ventricular arrhythmia by acebutolol in patients with acute myocardial infarction. British Heart Journal, 41(6), 654-659.

Reduction of early ventricular arrhythmia by acebutolol in patients with acute myocardial infarction. / Ahumada, G. G.; Karlsberg, R. P.; Jaffe, Allan S; Ambos, H. D.; Sobel, B. E.; Roberts, R.

In: British Heart Journal, Vol. 41, No. 6, 1979, p. 654-659.

Research output: Contribution to journalArticle

Ahumada, GG, Karlsberg, RP, Jaffe, AS, Ambos, HD, Sobel, BE & Roberts, R 1979, 'Reduction of early ventricular arrhythmia by acebutolol in patients with acute myocardial infarction', British Heart Journal, vol. 41, no. 6, pp. 654-659.
Ahumada, G. G. ; Karlsberg, R. P. ; Jaffe, Allan S ; Ambos, H. D. ; Sobel, B. E. ; Roberts, R. / Reduction of early ventricular arrhythmia by acebutolol in patients with acute myocardial infarction. In: British Heart Journal. 1979 ; Vol. 41, No. 6. pp. 654-659.
@article{d0e8fa0352934d508daceee6356029e0,
title = "Reduction of early ventricular arrhythmia by acebutolol in patients with acute myocardial infarction",
abstract = "To assess the effects of intravenously administered acebutolol (1-20 mg every 4 hours for 24 hours) on cardiac rhythm and performance, we studied 72 patients with evolving myocardial infarction. Twenty-five patients were treated with acebutolol beginning 6 hours after the first increase in the level of plasma creatine kinase. Enzymatically estimated infarct size was compared with that of 25 controls matched for predicted infarct size. Observed infarct sizes were not significantly different in the 2 groups (37±5 and 30±5 CK-gram equivalents, respectively). Mean heart rate, diastolic blood pressure, and cardiac output declined from control values during treatment with acebutolol, but remained within the normal range. Mean pulmonary artery pressure and pulmonary artery occlusive pressure were unchanged. In a group of 22 treated patients matched with 22 control subjects for frequency of ventricular extrasystoles, acebutolol effected a prompt reduction in frequencies of ventricular extrasystoles and repetitive arrhythmias, whereas values were not significantly changed in controls during the corresponding intervals. Accordingly, acebutolol may be a useful antiarrhythmic agent in selected patients with acute myocardial infarction without adversely altering haemodynamic stability or enzymatically estimated infarct size.",
author = "Ahumada, {G. G.} and Karlsberg, {R. P.} and Jaffe, {Allan S} and Ambos, {H. D.} and Sobel, {B. E.} and R. Roberts",
year = "1979",
language = "English (US)",
volume = "41",
pages = "654--659",
journal = "Heart",
issn = "1355-6037",
publisher = "BMJ Publishing Group",
number = "6",

}

TY - JOUR

T1 - Reduction of early ventricular arrhythmia by acebutolol in patients with acute myocardial infarction

AU - Ahumada, G. G.

AU - Karlsberg, R. P.

AU - Jaffe, Allan S

AU - Ambos, H. D.

AU - Sobel, B. E.

AU - Roberts, R.

PY - 1979

Y1 - 1979

N2 - To assess the effects of intravenously administered acebutolol (1-20 mg every 4 hours for 24 hours) on cardiac rhythm and performance, we studied 72 patients with evolving myocardial infarction. Twenty-five patients were treated with acebutolol beginning 6 hours after the first increase in the level of plasma creatine kinase. Enzymatically estimated infarct size was compared with that of 25 controls matched for predicted infarct size. Observed infarct sizes were not significantly different in the 2 groups (37±5 and 30±5 CK-gram equivalents, respectively). Mean heart rate, diastolic blood pressure, and cardiac output declined from control values during treatment with acebutolol, but remained within the normal range. Mean pulmonary artery pressure and pulmonary artery occlusive pressure were unchanged. In a group of 22 treated patients matched with 22 control subjects for frequency of ventricular extrasystoles, acebutolol effected a prompt reduction in frequencies of ventricular extrasystoles and repetitive arrhythmias, whereas values were not significantly changed in controls during the corresponding intervals. Accordingly, acebutolol may be a useful antiarrhythmic agent in selected patients with acute myocardial infarction without adversely altering haemodynamic stability or enzymatically estimated infarct size.

AB - To assess the effects of intravenously administered acebutolol (1-20 mg every 4 hours for 24 hours) on cardiac rhythm and performance, we studied 72 patients with evolving myocardial infarction. Twenty-five patients were treated with acebutolol beginning 6 hours after the first increase in the level of plasma creatine kinase. Enzymatically estimated infarct size was compared with that of 25 controls matched for predicted infarct size. Observed infarct sizes were not significantly different in the 2 groups (37±5 and 30±5 CK-gram equivalents, respectively). Mean heart rate, diastolic blood pressure, and cardiac output declined from control values during treatment with acebutolol, but remained within the normal range. Mean pulmonary artery pressure and pulmonary artery occlusive pressure were unchanged. In a group of 22 treated patients matched with 22 control subjects for frequency of ventricular extrasystoles, acebutolol effected a prompt reduction in frequencies of ventricular extrasystoles and repetitive arrhythmias, whereas values were not significantly changed in controls during the corresponding intervals. Accordingly, acebutolol may be a useful antiarrhythmic agent in selected patients with acute myocardial infarction without adversely altering haemodynamic stability or enzymatically estimated infarct size.

UR - http://www.scopus.com/inward/record.url?scp=0018756971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018756971&partnerID=8YFLogxK

M3 - Article

C2 - 465240

AN - SCOPUS:0018756971

VL - 41

SP - 654

EP - 659

JO - Heart

JF - Heart

SN - 1355-6037

IS - 6

ER -